Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT001 dose finding in moderate to severe COPD
NCT01566773Phase 2Completed
- Sponsor
- Pearl Therapeutics
- Start
- Mar 2012
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Pearl Therapeutics. Started Mar 2012; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01566773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01566773.